External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ECP 2023
Roche at

ECP 2023

September 09 - September 13
Dublin, Ireland / Virtual (Hybrid)
esp-congress.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Sep 9 / Roche
Comparison of data from two commercially available tissue-based comprehensive genomic profiling (CGP) solutions using AMP/ASCO/CAP guidelines and ESMO ESCAT
This study compared differences in data generated by the AVENIO Tumor Tissue CGP Kit and the TruSight Oncology 500 (TSO) assay - two commercially available pan-cancer solutions. Potential clinical implications of the data generated by both products is presented. Variant calls were acquired using manufacturer-provided software; key variant annotation outputs were variant tiers and ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) guideline inclusion per tumour type. Differences in the detection of tumour mutational burden and ESCAT biomarkers, including copy number alterations, were identified.
Oncology Pan-tumour ECP-2023

Sign up or login to unlock the full suite of MEDICALLY features
Sep 9 / Roche
Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples for Patient Identification in Two Phase 3 Trials of Zolbetuximab
Study evaluating the performance of the investigational VENTANA CLDN18 (43-14A) RxDx Assay for IHC detection of CLDN18.2 to help identify patients with LA unresectable or mG/GEJ adenocarcinoma who could possibly benefit from zolbetuximab therapy in the SPOTLIGHT and GLOW trials.
Oncology Gastric Cancer Gastroesophageal Cancer ECP-2023

Sign up or login to unlock the full suite of MEDICALLY features
Sep 9 / Roche
Predicting Cell-of-origin for Diffuse Large B-cell Lymphoma Patients (DLBCL) using Explainable Feature Based Model
This study compares use of two deep learning models for cell of origin classification of whole slide images of haematoxylin and eosin-stained pathology slides from patients with diffuse large B-cell lymphoma and identifies cellular features that impact on model prediction.
Oncology Diffuse large B cell lymphoma ECP-2023

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.